Potential New Drug Trial: BA-1049
Rho Kinase Inhibitor BA-1049 Moving Forward for CCM. The medicine being developed by BioAxone to treat CCM has been licensed to Neurelis to move forward to trials. Neurelis intends to…
News
Webinar – Dr. Issam Awad – Rapamycin, Atorvastatin, and more
A recording of this webinar is now available on our YouTube channel. Please join Dr. Issam Awad on Wednesday, June 16th at 7 pm ET, 4 pm PT for…
Biomarker Development Project in El Paso Seeking Participants
Texas Tech University Health Sciences Center El Paso has begun a project to identify the genetic factors that cause cerebral cavernous malformations (CCMs) and validate new potential blood biomarkers for…
Webinar – PIK3CA Mutation and CCM Lesion Growth
The recorded webinar is now available online on our YouTube channel. Join us on Tuesday, June 8th at 1 pm ET, 10 am PT for a webinar discussing…
New Research: Cancer-linked mutation accelerates growth of CCM lesions
What’s new? CCM lesions develop when blood vessel cells (endothelial cells) lose the function for one of the CCM genes. New research shows us that, for those lesions that are…
